by Barry101 | Nov 15, 2023 | Press Release
– Highlights continued execution across Ampligen® clinical development programs – Company is well positioned to achieve multiple value-driving milestones during remainder of 2023 and 2024 – Will host conference call and webcast today, November...
by Barry101 | Nov 14, 2023 | Press Release
Data published in The Journal for ImmunoTherapy of CancerOCALA, Fla., Nov. 14, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of results from the Phase 1 study at Roswell Park...
by Barry101 | Nov 9, 2023 | Press Release
OCALA, Fla., Nov. 09, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss the Company’s Q3 2023 operational and financial...
by Barry101 | Nov 8, 2023 | Press Release
Data presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting Longitudinal comparison of biomarkers in tumor microenvironment showed a gradual, durable response over time in T lymphotactic CXCR3 ligands and cytolytic factors Phase 2 study...
by Barry101 | Nov 6, 2023 | Press Release
Highlights AIM’s Significant Momentum and Ongoing Achievement of Clinical and Regulatory Milestones Urges Shareholders to Protect AIM’s Progress by Voting for the Company’s Board of Directors and Discarding Any Proxy Materials from the Activist Group...
